First Time Loading...

Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 906.1 DKK 2.15% Market Closed
Updated: Jul 21, 2024
Have any thoughts about
Novo Nordisk A/S?
Write Note

Intrinsic Value

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. [ Read More ]

The intrinsic value of one NOVO B stock under the Base Case scenario is 648.82 DKK. Compared to the current market price of 906.1 DKK, Novo Nordisk A/S is Overvalued by 28%.

Key Points:
NOVO B Intrinsic Value
Base Case
648.82 DKK
Overvaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Novo Nordisk A/S

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NOVO B stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Notes Created
1
Decisions Made
0
Last Decision Profit
0%
Decision Success Rate
0%

Novo Nordisk's Strong Q1 2024 Performance and Raised Full-Year Outlook
Earnings Call Summary

Novo Nordisk's Strong Q1 2024 Performance and Raised Full-Year Outlook

In Q1 2024, Novo Nordisk achieved a 24% increase in sales and a 30% rise in operating profit. The company raised its full-year outlook, driven by solid demand for its diabetes and obesity treatments, particularly GLP-1 therapies. North American sales grew by 35%, while international operations saw an 11% increase. Notably, obesity care sales soared by 42%, led by Wegovy. The company also reported a 32% rise in carbon emissions due to higher capital expenditure. Commitments to sustainability included a higher percentage of women in senior leadership roles and significant R&D milestones, such as the approval of the Wegovy label expansion in the U.S.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Novo Nordisk A/S

Current Assets 116.4B
Cash & Short-Term Investments 9.3B
Receivables 71.8B
Other Current Assets 35.4B
Non-Current Assets 182.5B
Long-Term Investments 1.7B
PP&E 98.2B
Intangibles 59.6B
Other Non-Current Assets 23B
Current Liabilities 165.6B
Accounts Payable 13B
Other Current Liabilities 152.6B
Non-Current Liabilities 34.4B
Long-Term Debt 16.8B
Other Non-Current Liabilities 17.6B
Efficiency

Earnings Waterfall
Novo Nordisk A/S

Revenue
244.2B DKK
Cost of Revenue
-37.5B DKK
Gross Profit
206.7B DKK
Operating Expenses
-97.3B DKK
Operating Income
109.4B DKK
Other Expenses
-20.1B DKK
Net Income
89.3B DKK

Free Cash Flow Analysis
Novo Nordisk A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

NOVO B Profitability Score
Profitability Due Diligence

Novo Nordisk A/S's profitability score is 86/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Exceptional 3-Year Average ROIC
Positive Gross Profit
86/100
Profitability
Score

Novo Nordisk A/S's profitability score is 86/100. The higher the profitability score, the more profitable the company is.

NOVO B Solvency Score
Solvency Due Diligence

Novo Nordisk A/S's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
76/100
Solvency
Score

Novo Nordisk A/S's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NOVO B Price Targets Summary
Novo Nordisk A/S

Wall Street analysts forecast NOVO B stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NOVO B is 957.77 DKK .

Lowest
Price Target
Not Available
Average
Price Target
957.77 DKK
6% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NOVO B?

Click here to dive deeper.

Competitive Landscape

Price Appreciation

NOVO B Price
Novo Nordisk A/S

1M 1M
-8%
6M 6M
+25%
1Y 1Y
+64%
3Y 3Y
+244%
5Y 5Y
+551%
10Y 10Y
+969%
Annual Price Range
906.1
52w Low
525.913
52w High
1 028
Price Metrics
Average Annual Return 36.48%
Standard Deviation of Annual Returns 24.51%
Max Drawdown -14%
Shares Statistics
Market Capitalization 4T DKK
Shares Outstanding 4 461 908 793
Percentage of Shares Shorted
N/A

NOVO B Return Decomposition
Main factors of price return

What is price return decomposition?

NOVO B News

Other Videos

Last Important Events
Novo Nordisk A/S

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Novo Nordisk A/S

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Novo Nordisk A/S Logo
Novo Nordisk A/S

Country

Denmark

Industry

Pharmaceuticals

Market Cap

4T DKK

Dividend Yield

1.42%

Description

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Contact

Bagsvaerd
Novo Alle 1
+4544448888.0
https://www.novonordisk.com/

IPO

1974-05-17

Employees

47 792

Officers

President, CEO & Member of Management Board
Mr. Lars Fruergaard Jorgensen
Executive VP, CFO & Member of the Management Board
Mr. Karsten Munk Knudsen
Executive VP of Product Supply, Quality & IT and Member of the Management Board
Mr. Henrik Ehlers Wulff
Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board
Ms. Camilla Sylvest
Executive VP of Development & Member of the Management Board
Dr. Martin Holst Lange
EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board
Dr. Marcus Schindler Ph.D.
Show More
Executive VP of International Operations & Member of the Management Board
Mr. Maziar Mike Doustdar
Executive VP of North America Operations & Member of Management Board
Mr. Douglas J. Langa
Executive VP, Head of Rare Disease & Member of Management Board
Mr. Ludovic Helfgott
Executive VP of Global People & Organisation and Member of Management Board
Ms. Tania Sabroe
Show Less

See Also

Discover More
What is the Intrinsic Value of one NOVO B stock?

The intrinsic value of one NOVO B stock under the Base Case scenario is 648.82 DKK.

Is NOVO B stock undervalued or overvalued?

Compared to the current market price of 906.1 DKK, Novo Nordisk A/S is Overvalued by 28%.